Investigating the relationship between movement initiation and beta bursts in patients with Parkinson’s disease by neurofeedback training

Does NeuroFeedback Training-linked suppression of beta bursts speed up movement initiation in Parkinson’s Disease patients? Part of the NFToPD study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12684957

Enrollment

Registered

2020-02-26

Start date

2018-08-01

Completion date

Unknown

Last updated

2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson’s disease (PD) Nervous System Diseases Parkinson’s disease (PD)

Interventions

This study was controlled through within-subject controls, randomized to the order of intervention and non-intervention activities. An additional level of control was added through the inclusion of he

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 25 to 80 years 2. Falls into one of the three categories: a. Diagnosis of Parkinson's disease with DBS electrodes implanted b. Diagnosis of Parkinson's disease without DBS electrodes implanted c. No diagnosis of Parkinson's disease, healthy volunteer

Exclusion criteria

Exclusion criteria: 1. Cognitive impairment (judged by the clinician taking consent as not having sufficient mental capacity to understand the study and its requirements). Including anyone who, in the opinion of the clinician taking consent is unlikely to retain sufficient mental capacity for the duration of their involvement in the study. 2. Severe motor impairment (judged by the clinician taking consent as not having sufficient motor capacity to perform the motor task in the study). 3. Unwilling to briefly withdraw the ongoing medications. 4. Severe visual impairment

Design outcomes

Primary

Measure	Time frame
1. Self-modulation of the targeted neural signal by the participants with neurofeedback training. This will be assessed by bioelectrical signals recorded during the neurofeedback training experiment at 2h. This will include the beta burst characteristic, average beta power, and coherence between the STN and cortex derived from the recording of local field potentials (LFPs) and electroencephalography (EEG) in cortical-basal ganglia-thalamic circuits such as sub-thalamic nucleus (STN) or sensorimotor cortex (C3 or C4). 2. Changes in motor performance associated with the neurofeedback training measured by reaction time and peak movement velocity derived from the original measurements such as the generated force in the pinch task at 2h	—

Measure

Time frame

1. Self-modulation of the targeted neural signal by the participants with neurofeedback training. This will be assessed by bioelectrical signals recorded during the neurofeedback training experiment at 2h. This will include the beta burst characteristic, average beta power, and coherence between the STN and cortex derived from the recording of local field potentials (LFPs) and electroencephalography (EEG) in cortical-basal ganglia-thalamic circuits such as sub-thalamic nucleus (STN) or sensorimotor cortex (C3 or C4). 2. Changes in motor performance associated with the neurofeedback training measured by reaction time and peak movement velocity derived from the original measurements such as the generated force in the pinch task at 2h

—

Secondary

Measure	Time frame
1. Neurofeedback control performance over the duration of the study measured through recorded data from the neurofeedback training task at 2h 2. How other symptoms related to Parkinson’s disease change with neurofeedback training. This will be assessed through records from the neurofeedback training, measurements from the motor task, the intensity of tremor recorded using a 3D accelerometer, the Unified Parkinson’s Disease Rating Scale (UPDRS) score and patient notes whether on or off medication at 2h. 3. The potential effect of the neurofeedback training in the DBS patients measured by the anatomy information of the DBS electrodes at 2h for the DBS patients. The researchers can investigate the correlations between the primary and secondary outcome measurements, to better understand the potential effect of the neurofeedback training. 4. The learning effect of repeated neurofeedback training at 2h, 2 days, and 4 days.	—

Measure

Time frame

1. Neurofeedback control performance over the duration of the study measured through recorded data from the neurofeedback training task at 2h 2. How other symptoms related to Parkinson’s disease change with neurofeedback training. This will be assessed through records from the neurofeedback training, measurements from the motor task, the intensity of tremor recorded using a 3D accelerometer, the Unified Parkinson’s Disease Rating Scale (UPDRS) score and patient notes whether on or off medication at 2h. 3. The potential effect of the neurofeedback training in the DBS patients measured by the anatomy information of the DBS electrodes at 2h for the DBS patients. The researchers can investigate the correlations between the primary and secondary outcome measurements, to better understand the potential effect of the neurofeedback training. 4. The learning effect of repeated neurofeedback training at 2h, 2 days, and 4 days.

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026